202 related articles for article (PubMed ID: 33834639)
1. Influence of repeated prostate-specific antigen screening on treatment pattern in a country with a limited social perception of prostate cancer: Korean national wide observational study.
Ko YH; Kim SW
Investig Clin Urol; 2021 May; 62(3):282-289. PubMed ID: 33834639
[TBL] [Abstract][Full Text] [Related]
2. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
3. Use of low free to total PSA ratio in prostate cancer screening: detection rates, clinical and pathological findings in Brazilian men with serum PSA levels <4.0 ng/mL.
Faria EF; Carvalhal GF; dos Reis RB; Tobias-Machado M; Vieira RA; Reis LO; Nogueira L; Machado RD; Freitas CH; Magnabosco WJ; Mauad EC; Carvalho AL
BJU Int; 2012 Dec; 110(11 Pt B):E653-7. PubMed ID: 22892057
[TBL] [Abstract][Full Text] [Related]
4. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer.
Heidenreich A; Bastian PJ; Bellmunt J; Bolla M; Joniau S; van der Kwast T; Mason M; Matveev V; Wiegel T; Zattoni F; Mottet N;
Eur Urol; 2014 Feb; 65(2):467-79. PubMed ID: 24321502
[TBL] [Abstract][Full Text] [Related]
5. A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.
Hugosson J; Roobol MJ; Månsson M; Tammela TLJ; Zappa M; Nelen V; Kwiatkowski M; Lujan M; Carlsson SV; Talala KM; Lilja H; Denis LJ; Recker F; Paez A; Puliti D; Villers A; Rebillard X; Kilpeläinen TP; Stenman UH; Godtman RA; Stinesen Kollberg K; Moss SM; Kujala P; Taari K; Huber A; van der Kwast T; Heijnsdijk EA; Bangma C; De Koning HJ; Schröder FH; Auvinen A;
Eur Urol; 2019 Jul; 76(1):43-51. PubMed ID: 30824296
[TBL] [Abstract][Full Text] [Related]
6. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study.
Hjertholm P; Fenger-Grøn M; Vestergaard M; Christensen MB; Borre M; Møller H; Vedsted P
Int J Cancer; 2015 Jan; 136(2):435-42. PubMed ID: 24905402
[TBL] [Abstract][Full Text] [Related]
7. Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand.
Matti B; Lyndon M; Zargar-Shoshtari K
BJU Int; 2021 Dec; 128 Suppl 3():11-17. PubMed ID: 32599662
[TBL] [Abstract][Full Text] [Related]
8. Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial.
Yli-Hemminki TH; Laurila M; Auvinen A; Määttänen L; Huhtala H; Tammela TL; Kujala PM
BJU Int; 2013 Oct; 112(6):735-41. PubMed ID: 23746332
[TBL] [Abstract][Full Text] [Related]
9. Impact of Accountable Care Organizations on Diagnostic Testing for Prostate Cancer.
Luckenbaugh AN; Hollenbeck BK; Kaufman SR; Yan P; Herrel LA; Skolarus TA; Norton EC; Schroeck FR; Jacobs BL; Miller DC; Hollingsworth JM; Shahinian VB; Borza T
Urology; 2018 Jun; 116():68-75. PubMed ID: 29630957
[TBL] [Abstract][Full Text] [Related]
10. Use of the prostate-specific antigen (PSA) test in the United States for men age ≥65, 1999-2015: Implications for practice interventions.
Shahangian S; Fan L; Sharma KP; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1352. PubMed ID: 33932150
[TBL] [Abstract][Full Text] [Related]
11. Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial.
Johnston TJ; Shaw GL; Lamb AD; Parashar D; Greenberg D; Xiong T; Edwards AL; Gnanapragasam V; Holding P; Herbert P; Davis M; Mizielinsk E; Lane JA; Oxley J; Robinson M; Mason M; Staffurth J; Bollina P; Catto J; Doble A; Doherty A; Gillatt D; Kockelbergh R; Kynaston H; Prescott S; Paul A; Powell P; Rosario D; Rowe E; Donovan JL; Hamdy FC; Neal DE;
Eur Urol; 2017 Mar; 71(3):381-388. PubMed ID: 27720537
[TBL] [Abstract][Full Text] [Related]
12. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
Beckmann K; Kinsella N; Olsson H; Wallerstedt Lantz A; Nordstrom T; Aly M; Adolfsson J; Eklund M; Van Hemelrijck M
BMC Urol; 2019 Aug; 19(1):73. PubMed ID: 31383015
[TBL] [Abstract][Full Text] [Related]
13. Low-Value Prostate Cancer Screening Among Older Men Within the Veterans Health Administration.
Radomski TR; Huang Y; Park SY; Sileanu FE; Thorpe CT; Thorpe JM; Fine MJ; Gellad WF
J Am Geriatr Soc; 2019 Sep; 67(9):1922-1927. PubMed ID: 31276198
[TBL] [Abstract][Full Text] [Related]
14. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
[TBL] [Abstract][Full Text] [Related]
15. Practice patterns of urologists in managing Korean men aged 40 years or younger with high serum prostate-specific antigen levels.
Yoo DS; Woo SH; Cho S; Kang SH; Kim SJ; Park SY; Lee SH; Jeon SH; Park J
Urology; 2014 Jun; 83(6):1339-43. PubMed ID: 24726151
[TBL] [Abstract][Full Text] [Related]
16. Low-Value Prostate-Specific Antigen Test for Prostate Cancer Screening and Subsequent Health Care Utilization and Spending.
Kim DD; Daly AT; Koethe BC; Fendrick AM; Ollendorf DA; Wong JB; Neumann PJ
JAMA Netw Open; 2022 Nov; 5(11):e2243449. PubMed ID: 36413364
[TBL] [Abstract][Full Text] [Related]
17. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer.
Kim SP; Karnes RJ; Nguyen PL; Ziegenfuss JY; Thompson RH; Han LC; Shah ND; Smaldone MC; Gross CP; Frank I; Weight CJ; Beebe TJ; Tilburt JC
BJU Int; 2014 May; 113(5b):E106-11. PubMed ID: 24053213
[TBL] [Abstract][Full Text] [Related]
18. Use of the prostate-specific antigen test in the U.S. for men age 30 to 64 in 2011 to 2017 using a large commercial claims database: Implications for practice interventions.
Shahangian S; Sharma KP; Fan L; Siegel DA
Cancer Rep (Hoboken); 2021 Aug; 4(4):e1365. PubMed ID: 33934557
[TBL] [Abstract][Full Text] [Related]
19. Health disparities in clinical practice patterns for prostate cancer screening by geographic regions in the United States: a multilevel modeling analysis.
Garg V; Raisch DW; Selig JP; Thompson TA
Prostate Cancer Prostatic Dis; 2013 Jun; 16(2):193-203. PubMed ID: 23399779
[TBL] [Abstract][Full Text] [Related]
20. Influence of blood prostate specific antigen levels at age 60 on benefits and harms of prostate cancer screening: population based cohort study.
Carlsson S; Assel M; Sjoberg D; Ulmert D; Hugosson J; Lilja H; Vickers A
BMJ; 2014 Mar; 348():g2296. PubMed ID: 24682399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
